Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade

Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) shares reached a new 52-week high on Monday after Chardan Capital raised their price target on the stock from $60.00 to $73.00. Chardan Capital currently has a buy rating on the stock. Palvella Therapeutics traded as high as $63.39 and last traded at $62.25, with a volume of 278395 shares traded. The stock had previously closed at $59.59. PVLA has been the topic of a number of other rep…